Champions OncologyCSBR +7.98%64 Days Payable is 60.53 as of Jan. 2026, which is 6% below its 10-year median of 64.22. GuruFocus rates CSBR with a GF Score™ of 64/100 and a GF Value™ of $6.62 (Fairly Valued). The stock has 2 warning signs investors should review. Among 707 Biotechnology companies, Champions Oncology ranks worse than 63.51% on this metric.
The historical rank and industry rank for Champions Oncology's Days Payable or its related term are showing as below:
CSBR'
s Days Payable Range Over the Past 10 Years
Min: 36.77 Med: 64.22 Max: 70.49
Current: 60.3
During the past 13 years, Champions Oncology's highest Days Payable was 70.49. The lowest was 36.77. And the median was 64.22.
CSBR's Days Payable is ranked worse than 63.51% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs CSBR: 60.30
Champions Oncology's Days Payable
declined
from Jan. 2025 (68.59) to Jan. 2026 (60.53).
It may suggest that Champions Oncologyaccelerated paying its suppliers.
Champions Oncology Days Payable Related Terms
Champions Oncology Days Payable Historical Data
* Premium members only.
The historical data trend for Champions Oncology's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Champions Oncology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's Days Payable distribution charts can be found below:
* The bar in red indicates where Champions Oncology's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Champions Oncology's Days Payable for the fiscal year that ended in Apr. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Champions Oncology (CSBR) has a Days Payable of 60.53 as of Jan. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Champions Oncology and its competitors. This is near median its historical median of 64.22. Over the past decade, Champions Oncology's Days Payable has ranged from 36.77 to 70.49. According to the industry distribution chart, Champions Oncology ranks #449 out of 707 companies in the Biotechnology industry, placing it in the top 63.5%.
Is Champions Oncology's Days Payable too high?
Champions Oncology's current Days Payable of 60.53 is near median its 10-year median of 64.22. Over the past 10 years, this metric has ranged from a low of 36.77 to a high of 70.49. The Biotechnology industry median Days Payable is 113.76. Champions Oncology's value of 60.53 is 46.8% below this industry median. Based on the distribution chart, Champions Oncology ranks #449 out of 707 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's Days Payable compare to ANVS and HYFT?
According to the Biotechnology industry distribution chart, Champions Oncology ranks #449 out of 707 companies for Days Payable. This places Champions Oncology in the lower half of its industry. The industry median Days Payable is 113.76. Champions Oncology's value of 60.53 is 46.8% below this benchmark. Historically, Champions Oncology's own Days Payable has ranged from 36.77 to 70.49 over the past decade. While the company's 10-year median is 64.22 vs. the industry median of 113.76, Champions Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Champions Oncology's current Days Payable of 60.53 is 46.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Champions Oncology and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Champions Oncology's current Days Payable is 60.53, which is near median its own 10-year median of 64.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Fairly Valued. The stock's GF Value™ is $6.62, compared to a current price of $6.63 — trading 0.2% above its estimated fair value. The current Days Payable is 60.53, which is near median its 10-year median of 64.22 and 46.8% below the Biotechnology industry median of 113.76. Champions Oncology's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Champions Oncology (CSBR), the current Days Payable is 60.53 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Champions Oncology (CSBR) Overvalued in 2026?
Based on GuruFocus' analysis, Champions Oncology stock appears to be overvalued.
The current stock price of $6.63 is trading 0.2% above its estimated GF Value™ of $6.62.
GuruFocus considers Champions Oncology to be Fairly Valued.
Key valuation signals for CSBR:
Days Payable: 60.53 (near median its 10-year median of 64.22)
GF Value™: $6.62 vs. price of $6.63 (0.2% above fair value)
Industry Position: 46.8% below the Biotechnology median (#449 of 707)
No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score
Get the complete analysis for CSBR
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBR has been successfully added to your 
